Lasa Supergenerics DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1.06×	0.99×	0.76×	1.14×	0.91×
	1.06×	1.01×	3.21×	2.25×	2.11×
	−231.8%	−136.9%	−4.2%	−8.2%	−15.4%
	0.30×	0.30×	1.13×	0.66×	0.79×
	1.34×	1.34×	1.21×	1.56×	1.39×
	−104.3%	−54.3%	−14.2%	−21.5%	−32.6%
	−51.1%	−51.1%	−16.4%	−20.2%	−32.7%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

LASA₹4.67

Lasa Supergenerics Limited

· Pharma & Health

₹ CrorePeersMANGALAM BIOFILCHEM ORTINGLOBE VINEETLAB KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹23.4 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.91	1.14	0.76	0.99	1.06
Interest Burden (Pretax/EBIT) ×	2.11	2.25	3.21	1.01	1.06
EBIT Margin %	-15.45	-8.15	-4.24	-136.91	-231.78
Asset Turnover ×	0.79	0.66	1.13	0.30	0.30
Financial Leverage (Assets/Equity) ×	1.39	1.56	1.21	1.34	1.34
ROE (5-step product, year-end total equity) %	-32.62	-21.45	-14.20	-54.33	-104.33
ROE (owners' profit / average owners' equity) %	-32.65	-20.22	-16.36	-51.13	-51.13

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.